monoamine oxidase

Monoamine oxidase, an enzyme comprising various polypeptides, catalyzes the oxidative deamination of diverse biological amines within both brain and peripheral tissues, yielding hydrogen peroxide in the process. This enzyme is crucial for regulating synaptic transmission, emotional behavior, and other cerebral functions [1] [2].

Monoamine Oxidase B inhibitor 1 is a potent, reversible, orally active, and selective monoamine oxidase B (MAO-B) inhibitor (IC50 = 0.02 nM) capable of crossing the blood-brain barrier (BBB). It exhibits antioxidant and anti-neuroinflammatory activities and can be used in the study of Parkinson's disease[1].

Monoamine Oxidase B inhibitor 2 is a potent, reversible, orally active, and selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 1.33 nM, capable of crossing the blood-brain barrier (BBB). It exhibits antioxidant and anti-neuroinflammatory activities and is useful in the study of Parkinson's disease [1].

Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a potent dual inhibitor of monoamine oxidase (MAO) and aromatase, with IC50 values of 39 nM for MAO-B and 31 nM for aromatase. It holds significant potential for research in neurological disorders and breast cancer [1].

Monoamine OxidaseB inhibitor 6 (Compound BT5) is a highly selective, reversible, and competitive MAO-B inhibitor capable of crossing the blood-brain barrier, with an IC50 of 0.11 μM. It exhibits antioxidant and neuroprotective properties, making it suitable for research into neurodegenerative diseases.

Monoamine OxidaseB inhibitor 5 (Compound 16d) is a reversible and selective inhibitor of monoamine oxidase B (hMAO-B), with an IC50 value of 67.3 nM and a Ki of 82.5 nM. It exhibits favorable pharmacokinetic properties and low toxicity in rat models. Additionally, this compound alleviates motor impairments in a Parkinson's mouse model induced by MPTP, and it is characterized by its ability to penetrate the blood-brain barrier (BBB).

Monoamine Oxidase B Inhibitor 4 (compound 1l), with a potent IC50 value of 8.3 nM, is a selective human monoamine oxidase-B (hMAO-B) inhibitor. This compound demonstrates anti-neuroinflammatory properties and exhibits low neurotoxicity. It effectively inhibits the release of NO, TNF-α, and IL-1β induced by LPS and Aβ1-42, and additionally mitigates the cytotoxic effects triggered by Aβ(1-42) .

MAO-IN-1 is a potent monoamine oxidase B (MAO B) inhibitor (IC50: 20 nM) for the study of neurologically related diseases.

2614W94 is a selective inhibitor of MAO-A with IC50 of 5 nM and Ki of 1.6 nM.

MAO-B-IN-1 is a monoamine oxidase B inhibitor and can be used for the research of neurological diseases.

PAT-1251 is an inhibitor of LOXL2 with IC50s of 10, 0.12, and 0.16 μM for the mouse, rat, and dog and can be used in studies about fibrotic diseases.

CX-157 (KP 157) is a novel monoamine oxidase-A (MAO-A) inhibitor for the study of depression-like neurological disorders and cancer.

Medifoxamine (LG 152) is a selective non-monoamine oxidase inhibitor that exhibits antidepressant activity through inhibition of 5 HT reuptake.Medifoxamine preferentially inhibits dopamine reuptake.

BW-1370U87 is a reversible competitive monoamine oxidase-A inhibitor for the study of depression and other CNS disorders.

CCT365623 is an orally bioavailable Lysyl Oxidase inhibitor with good anti-LOX potency, selectivity, pharmacokinetic properties, as well as anti-metastatic efficacy.

Ladostigil (Ladostigil free base) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO) with inhibitory effects on MAO-B and AChE, with IC50 values of 37.1 and 31.8 μM, respectively.Ladostigil possesses anti-inflammatory, antioxidant, and neuroprotective activities, and may be used in studies of depression and Alzheimer's disease.

Eckol inhibits ultraviolet B-induced cell damage by a decrease in oxidative stress in human keratinocytes.This compound is unstable in powder form and other related salt forms are recommended.

Sembragiline (EVT-302) is a selective MAO-B inhibitor for the study of Alzheimer's disease (AD).

Atibeprone is a MAO-B inhibitor with antidepressant activity for the study of Parkinson's disease.

MAO-B-IN-5 is a potent, selective, and orally active MAO-B inhibitor with an IC50 of 0.204 μM, showing potential for research in Parkinson's disease (PD) [1].

Pargyline (Pargylamine) is a monoamine oxidase inhibitor with antihypertensive properties.

Iproniazid Phosphate is a non-selective, irreversible monoamine oxidase inhibitor (MAOI).

Tranylcypromine (2-PCPA) hydrochloride (SKF-385 HCl), a Monoamine Oxidase inhibitor, is effective in the treatment of major depression, dysthymic disorder, and atypical depression.

Hydroxylamine hydrochloride(Hydroxylammonium chloride) is a selective and potent monoamine oxidase (MAO) inhibitor with inhibitory effects on platelet aggregation.Hydroxylamine hydrochloride is an intermediate in organic synthesis and can be used to synthesize other active compounds.